Mesoblast Ltd (MESO)vsModerna Inc (MRNA)
MESO
Mesoblast Ltd
$15.12
-2.33%
HEALTHCARE · Cap: $2.01B
MRNA
Moderna Inc
$198.88
+2.08%
HEALTHCARE · Cap: $69.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 1753% more annual revenue ($2.23B vs $120.25M). MESO leads profitability with a -47.8% profit margin vs -141.4%. MESO earns a higher WallStSmart Score of 26/100 (F).
MESO
Avoid26
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.5%
Fair Value
$58.14
Current Price
$15.12
$43.02 discount
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$198.88
$64.19 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 390.7% year-over-year
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
ROE of -18.2% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Trading at 11.7x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MESO
The strongest argument for MESO centers on Revenue Growth, Debt/Equity. Revenue growth of 390.7% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : MESO
The primary concerns for MESO are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
MESO profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MESO is growing revenue faster at 390.7% — sustainability is the question.
MESO generates stronger free cash flow (-9M), providing more financial flexibility.
Bottom Line
MESO scores higher overall (26/100 vs 21/100) and 390.7% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Mesoblast Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?